AB SCIEX推出创新的蛋白质组学质谱应用新技术
TripleTOF™ 5600质谱系统
参考英文原文：
Leading proteomics researchers are gathering at the HUPO 2011 meeting in Geneva, Switzerland, to define new short-term milestones for the Human Proteome Project (HPP). This global collaboration aims to map the entire human proteome over the next five to ten years. The project will be introduced to HUPO delegates at an AB SCIEX workshop on 5th September, opening with an introduction by the HPP leader, Pierre Legrain.
What is the HPP?
The Human Proteome Project is a global collaboration between proteomics researchers, a HUPO initiative that aims to assign and characterise all proteins in the human body. The project has two main directions: chromosome-based HPP (cHPP), focusing on annotating subsets of proteins for each chromosome, and biology disease-driven HPP (bdHPP), aiming to answer biological and disease-related questions. To identify, quantify and annotate all human protein-coding genes, the HPP will use three tools: mass spectrometry, antibody affinity and bioinformatics. For each method the HPP is defining guidelines with recommendations for experimental procedures, sample handling and data analysis.
The ultimate goal is to produce high-quality results that would be universally available to researchers all over the world. In the long term, the HPP aims to take proteomics beyond research and into clinical applications.
Why is the project starting now?
Planning for the HPP began several years ago, but the tools that will be needed to achieve the project’s goals have only recently become available. Mass spectrometry technologies have significantly improved in recent years, particularly in terms of reproducibility, throughput, resolution, and accuracy and quality of the analysis. These improvements should allow sufficient accuracy for detecting and quantifying diverse proteins, even at low level of concentration. New technologies also make it possible to compare databases from different tissues and experiments to study the presence and level of expression of proteins in a sample, which is a key element of the HPP.
For example, the SWATH™ Acquisition technique, which was developed in collaboration with Prof Ruedi Aebersold and his colleagues at the ETH Zürich, is the first mass spectrometry-based technique that allows simultaneous quantitative and qualitative detection of all proteins and peptides in a sample - from a single analysis - in a fast, accurate, and reproducible manner. The development of SWATH Acquisition was made possible with the superior capabilities of the AB SCIEX TripleTOF™ 5600 System, which combines ultra-high acquisition speed with quantitative capabilities, accurate mass and high resolution.
What will be the main challenges?
The two main challenges for the HPP will be to convince enough large research laboratories to join the consortium, and to ensure sufficient quantitation to develop such large-scale databases. In the long term, the HPP will face a third challenge in convincing clinics to use mass spectrometry for diagnosis.
In order to achieve the HPP’s goals, large and influential proteomics research groups will be needed. Each member of the consortium will be asked to focus on one disease or biological question, to follow the guidelines and to accept open cross-analysis and sharing of their results before publishing.
In addition to ensuring high quality and reproducibility of the results, the consortium needs excellent quantitation to produce protein libraries of reference proteins. This requires sensitive high-power mass spectrometers, such as the recently developed TripleTOF 5600.
Clinics traditionally use antibody- based methods for diagnostics, a limited technique that sometimes cannot produce the required results. In order to apply human proteomics discovery to clinical use in the future, clinics will need to convert to mass spectrometry-based approaches.
What is AB SCIEX’s role?
AB SCIEX, a global leader in life science analytical technologies, is a member of the HPP’s Industry Advisory Board and is sponsoring a series of workshops at HUPO.
The HPP workshop will be followed by two further workshops focusing on new mass spectrometry technologies and workflows in peptide quantitation, including SWATH Acquisition. The workshops are open to all HUPO 2011 delegates, and will consist of talks from leading proteomics researchers from around the world, as well as from HUPO and AB SCIEX. HUPO 2011 takes place from 3-7 September, in Geneva, Switzerland.
AB SCIEX has contributed significantly to recent advances in mass spectrometry technology that could greatly benefit the HPP research, and offers a complete range of TripleTOF™, QTRAP®, Triple Quad™ and TOF/TOF™ Systems, as well as advanced software and the ground-breaking SelexION™ Technology.